Finance

Beta
Lists
TSHA:NASDAQ
Taysha Gene Therapies Inc
$6.34
+2.09%
(+0.13) 1D
$6.26
-1.22% (-0.078)
Pre-market
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TSHA...
Open
$6.11
High
$6.46
Low
$6.10
Mkt. cap
1.82B
Avg. vol.
2.86M
Volume
0.00
52-wk high
$7.30
52-wk low
$2.25
EPS
-$0.38
Beta
1.19
Shares outstanding
287.36M
No. of employees
99
Open
$6.11
High
$6.46
Low
$6.10
Mkt. cap
1.82B
Avg. vol.
2.86M
Volume
0.00
52-wk high
$7.30
52-wk low
$2.25
EPS
-$0.38
Beta
1.19
Shares outstanding
287.36M
No. of employees
99
News stories
From sources across the web
About Taysha Gene Therapies Inc
CEO-
Employees99
Founded2019
HeadquartersDallas, Texas, United States
SectorBiotechnology
Websitetayshagtx.com
Analyst ratings
Based on 8 analysts giving stock ratings to TSHA in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for TSHA in the last 3 months.
Highest
Current $6.34
$17.00 (+168.14%)
Average
$12.50 (+97.16%)
Lowest
$10.00 (+57.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Keith Tapper CFA
BMO Capital
Buy
Maintained
$14.00
+120.8%
06/23/2026
Unknown Analyst
Jefferies
Buy
Maintained
$13.00
+105%
06/23/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$11.00
+73.5%
06/23/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$10.00
+57.7%
06/22/2026
Gil Blum
Needham
Buy
Reiterated
$12.00
+89.3%
06/22/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
$10.00
+57.7%
06/01/2026
Unknown Analyst
Bank of America Securities
Buy
Reiterated
$9.00
+42%
05/08/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$17.00
+168.1%
05/06/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$11.00
+73.5%
05/07/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$12.00
+89.3%
05/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$19.00
+199.7%
03/24/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$11.00
+73.5%
03/19/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$11.00
+73.5%
03/20/2026
Biren Amin
Piper Sandler
Buy
Maintained
$9.00
+42%
02/25/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.12 / -$0.10
-22.45%miss
Revenue / Est. (USD)
- / 758.33K
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.99M
-
5.48M
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20.14M
25.74M
24.95M
33.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.60M
8.28M
8.83M
9.68M
Operating expense
28.74M
34.02M
33.78M
43.49M
Total operating expenses
28.74M
34.02M
33.78M
43.49M
Operating income
-26.75M
-34.02M
-28.30M
-43.49M
Other non operating income
-510.00K
-1.86M
3.76M
-31.00K
EBT including unusual items
-26.88M
-32.73M
-27.85M
-42.41M
EBT excluding unusual items
-25.42M
-32.73M
-21.68M
-40.94M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.88M
-32.73M
-27.85M
-42.41M
Net profit margin
-1,353.58%
-
-507.77%
-
Earnings per share
-0.08
-0.09
-0.07
-0.11
Interest and investment income
1.86M
3.17M
2.87M
2.59M
Interest expense
-17.00K
-15.00K
-12.00K
-9.00K
Net interest expenses
1.84M
3.15M
2.86M
2.58M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.48M
-33.74M
-28.00M
-43.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of TSHA
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer